Company Filing History:
Years Active: 2020-2021
Title: Seung Mi Kim: Innovator in Cancer Treatment
Introduction
Seung Mi Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of three patents, his work focuses on developing biomarkers and methods for predicting susceptibility to various cancer treatments.
Latest Patents
One of Seung Mi Kim's latest patents is a combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET). This invention relates to a biomarker for predicting susceptibility to an MET inhibitor, specifically for stomach cancer or lung cancer. The method provides an excellent effect of predicting susceptibility to the MET inhibitor, making it a valuable tool in cancer treatment.
Another significant patent is a biomarker for predicting sensitivity to an EGFR-targeting agent. This disclosure introduces a new biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, which includes a RON (Recepteur d'Origine Nantais) gene. The invention also encompasses a composition for predicting susceptibility, a method for enhancing susceptibility, and a kit for predicting susceptibility to the EGFR-targeted agent. This innovation is particularly effective in treating colon cancer.
Career Highlights
Seung Mi Kim has worked with notable companies such as Wellmarker Bio Co., Ltd. and The Asan Foundation. His experience in these organizations has contributed to his expertise in cancer research and treatment methodologies.
Collaborations
Some of his coworkers include Dong Hoon Jin and Seung Woo Hong, who have collaborated with him on various projects related to cancer treatment and biomarker development.
Conclusion
Seung Mi Kim's innovative work in cancer treatment through his patented inventions highlights his significant contributions to medical research. His focus on biomarkers and treatment methods positions him as a key figure in the ongoing fight against cancer.